Nuwellis Inc (NUWE)

$5.54 -0.10 (-1.77%)
Market Cap 582,000.00
Revenue (ttm) 8.74M
Net Income (ttm) -11.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -127.80%
Debt to Equity Ratio 0.00
Volume 115,900
Avg Vol 1,276,751
Day's Range N/A - N/A
Shares Out 105,000.00
Stochastic %K 67%
Beta 0.00
Analysts Hold
Price Target $11.00

Company Profile

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and...

Industry: Medical Devices
Sector: Healthcare
Phone: 952 345 4200
Address:
12988 Valley View Road, Eden Prairie, United States
IAMEXITLIQUIDITY
IAMEXITLIQUIDITY Aug. 18 at 1:44 PM
$NUWE she will go shortly... need to recoup some $CRE losses... she's a beauty when she runs and has no reason not to today
0 · Reply
bghom
bghom Aug. 18 at 1:19 PM
Sometimes it feels like $BGM is the sleeper in this group. While $WULF has Google, $BTAI has FDA, and $NUWE has low float hype—$BGM is still sitting low waiting for a spark.
0 · Reply
ogagbolo
ogagbolo Aug. 18 at 1:04 PM
$NUWE has all the ingredients for a squeeze. Low float, new patent, and traders piling in. Will it hold up longer than the last time, or fade fast? Watching with $BGM and $WULF on the side.
0 · Reply
hajjah
hajjah Aug. 18 at 12:55 PM
$NUWE traders are hyped but cautious—reverse splits in the past still haunt some. Still, low float can mean fireworks. Compared to $BGM and $BTAI, this one’s pure volatility play.
0 · Reply
roy30
roy30 Aug. 18 at 12:46 PM
$NUWE might only need volume to go crazy. That patent news and low float setup is hard to ignore. Watching this alongside $WULF and $BGM could create some wild sympathy plays.
0 · Reply
ola31
ola31 Aug. 18 at 12:28 PM
Noticing a rotation: $BTAI for biotech bulls, $NUWE for low float momentum, $WULF for AI/HPC, $BGM for robotics. Different themes, same energy—speculation is everywhere.
0 · Reply
BB_88_
BB_88_ Aug. 18 at 12:23 PM
$NUWE this hasn’t made a rocket run in a long long time
0 · Reply
anthony78w
anthony78w Aug. 18 at 12:23 PM
$BTAI bulls calling this “the beginning of the squeeze.” FDA optimism + Phase 3 talk + possible buyout chatter = fuel. Combine that biotech momentum with $NUWE’s volatility and $BGM’s robotics angle, and small caps are buzzing today.
0 · Reply
ophinh
ophinh Aug. 18 at 12:19 PM
$NUWE low float madness is here again. Patent win + volatility = recipe for fireworks. Watching how this trades compared to $BGM and $WULF, both popularity for totally different reasons.
0 · Reply
topstockalerts
topstockalerts Aug. 18 at 12:02 PM
$NUWE waking up..
0 · Reply
Latest News on NUWE
Nuwellis, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 15, 2025, 8:15 AM EDT - 3 days ago

Nuwellis, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Nuwellis, Inc. (NUWE) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 2:37 PM EDT - 3 days ago

Nuwellis, Inc. (NUWE) Q2 2025 Earnings Call Transcript

Nuwellis, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 14, 2025, 8:15 AM EDT - 4 days ago

Nuwellis, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

Nuwellis to Exit International Operations to Accelerate U.S. Revenue Growth and Strategic Focus

Aug 7, 2025, 8:15 AM EDT - 11 days ago

Nuwellis to Exit International Operations to Accelerate U.S. Revenue Growth and Strategic Focus

Nuwellis Postpones Second Quarter 2025 Earnings Release and Conference Call to August 14, 2025

Aug 6, 2025, 8:15 AM EDT - 12 days ago

Nuwellis Postpones Second Quarter 2025 Earnings Release and Conference Call to August 14, 2025

Nuwellis Announces the First Successful Outpatient Application of the Aquadex Smartflow® System Under New CMS Code

Aug 5, 2025, 8:15 AM EDT - 13 days ago

Nuwellis Announces the First Successful Outpatient Application of the Aquadex Smartflow® System Under New CMS Code

Nuwellis Stockholders Approve All Proposals at Special Meeting

Aug 4, 2025, 5:24 PM EDT - 13 days ago

Nuwellis Stockholders Approve All Proposals at Special Meeting

Nuwellis Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 23, 2025, 8:45 AM EDT - 26 days ago

Nuwellis Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Nuwellis Regains Compliance with Nasdaq Listing Requirements

Jul 23, 2025, 8:15 AM EDT - 26 days ago

Nuwellis Regains Compliance with Nasdaq Listing Requirements

Nuwellis, Inc. To Report Second Quarter 2025 Financial Results on August 12, 2025

Jul 22, 2025, 8:15 AM EDT - 27 days ago

Nuwellis, Inc. To Report Second Quarter 2025 Financial Results on August 12, 2025

Nuwellis Announces Termination of REVERSE-HF Clinical Trial to Focus on Strategic Growth in Outpatient Heart Failure Care

Jul 17, 2025, 7:35 AM EDT - 4 weeks ago

Nuwellis Announces Termination of REVERSE-HF Clinical Trial to Focus on Strategic Growth in Outpatient Heart Failure Care

Nuwellis Secures New U.S. Patent, Strengthening Its Position as a Leader in Fluid Management Innovation

Jul 15, 2025, 4:05 PM EDT - 4 weeks ago

Nuwellis Secures New U.S. Patent, Strengthening Its Position as a Leader in Fluid Management Innovation

Nuwellis Appoints John Erb as Chief Executive Officer

Jul 2, 2025, 8:15 AM EDT - 6 weeks ago

Nuwellis Appoints John Erb as Chief Executive Officer

Nuwellis Announces Closing of $5.0 Million Underwritten Public Offering Including Full Exercise of Overallotment Option

Jun 10, 2025, 4:15 PM EDT - 2 months ago

Nuwellis Announces Closing of $5.0 Million Underwritten Public Offering Including Full Exercise of Overallotment Option

Nuwellis Announces Pricing of $4.3 Million Underwritten Public Offering

Jun 9, 2025, 9:15 AM EDT - 2 months ago

Nuwellis Announces Pricing of $4.3 Million Underwritten Public Offering

Nuwellis, Inc. (NUWE) Q1 2025 Earnings Call Transcript

May 13, 2025, 10:50 AM EDT - 3 months ago

Nuwellis, Inc. (NUWE) Q1 2025 Earnings Call Transcript

Nuwellis, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

May 13, 2025, 7:00 AM EDT - 3 months ago

Nuwellis, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

Nuwellis Contracts with KDI Precision Manufacturing to Strengthen Production and Improve Operational Efficiency

May 12, 2025, 7:00 AM EDT - 3 months ago

Nuwellis Contracts with KDI Precision Manufacturing to Strengthen Production and Improve Operational Efficiency

Nuwellis Expands Aquadex® for Pediatric Fluid Management to Two New Hospital Systems

May 8, 2025, 7:00 AM EDT - 3 months ago

Nuwellis Expands Aquadex® for Pediatric Fluid Management to Two New Hospital Systems

Nuwellis Expands IP Portfolio with Patent That Reduces Clinical Burden, Preserves Precision

Apr 24, 2025, 7:00 AM EDT - 4 months ago

Nuwellis Expands IP Portfolio with Patent That Reduces Clinical Burden, Preserves Precision

Nuwellis, Inc. To Report First Quarter 2025 Financial Results on May 13, 2025

Apr 22, 2025, 4:05 PM EDT - 4 months ago

Nuwellis, Inc. To Report First Quarter 2025 Financial Results on May 13, 2025

Nuwellis, Inc. (NUWE) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 12:23 PM EDT - 5 months ago

Nuwellis, Inc. (NUWE) Q4 2024 Earnings Call Transcript

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results

Mar 11, 2025, 8:00 AM EDT - 5 months ago

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results

Nuwellis Announces Retirement of Nestor Jaramillo, Jr. as President and CEO

Feb 24, 2025, 4:05 PM EST - 6 months ago

Nuwellis Announces Retirement of Nestor Jaramillo, Jr. as President and CEO

JACC: Heart Failure Paper Reports Promising Findings of Aquadex Therapy in Updated AVOID-HF Study Analysis

Feb 20, 2025, 8:00 AM EST - 6 months ago

JACC: Heart Failure Paper Reports Promising Findings of Aquadex Therapy in Updated AVOID-HF Study Analysis

Nuwellis, Inc. To Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025

Feb 18, 2025, 4:15 PM EST - 6 months ago

Nuwellis, Inc. To Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025

Nuwellis, Inc. (NUWE) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 11:02 AM EST - 9 months ago

Nuwellis, Inc. (NUWE) Q3 2024 Earnings Call Transcript

Nuwellis, Inc. Announces Third Quarter 2024 Financial Results and Recent Highlights

Nov 11, 2024, 8:00 AM EST - 10 months ago

Nuwellis, Inc. Announces Third Quarter 2024 Financial Results and Recent Highlights

Nuwellis Announces Exercise of Warrants for $5.1 Million of Gross Proceeds

Nov 5, 2024, 9:28 AM EST - 10 months ago

Nuwellis Announces Exercise of Warrants for $5.1 Million of Gross Proceeds

Nuwellis Receives Increased Reimbursement Rate for Aquadex SmartFlow® Therapy from the Centers for Medicare and Medicaid

Nov 4, 2024, 8:30 AM EST - 10 months ago

Nuwellis Receives Increased Reimbursement Rate for Aquadex SmartFlow® Therapy from the Centers for Medicare and Medicaid

Nuwellis Announces Preliminary Results for Third Quarter of 2024

Nov 1, 2024, 4:15 PM EDT - 10 months ago

Nuwellis Announces Preliminary Results for Third Quarter of 2024

Nuwellis Welcomes University of Iowa Health Care Stead Family Children's Hospital as Newest Pediatric Customer

Oct 31, 2024, 8:00 AM EDT - 10 months ago

Nuwellis Welcomes University of Iowa Health Care Stead Family Children's Hospital as Newest Pediatric Customer

Nuwellis, Inc. To Report Third Quarter 2024 Financial Results on November 11, 2024

Oct 23, 2024, 4:15 PM EDT - 10 months ago

Nuwellis, Inc. To Report Third Quarter 2024 Financial Results on November 11, 2024

Nuwellis to Present at the Third Annual ROTH Healthcare Opportunities Conference

Sep 25, 2024, 4:15 PM EDT - 11 months ago

Nuwellis to Present at the Third Annual ROTH Healthcare Opportunities Conference

Nuwellis Announces Pricing of $916,000 Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Aug 23, 2024, 9:00 AM EDT - 1 year ago

Nuwellis Announces Pricing of $916,000 Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Nuwellis, Inc. (NUWE) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 12:39 PM EDT - 1 year ago

Nuwellis, Inc. (NUWE) Q2 2024 Earnings Call Transcript

Nuwellis, Inc. Announces Second Quarter 2024 Financial Results

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Nuwellis, Inc. Announces Second Quarter 2024 Financial Results

Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical's QUELIMMUNE™ Therapy at Cincinnati Children's

Jul 26, 2024, 9:00 AM EDT - 1 year ago

Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical's QUELIMMUNE™ Therapy at Cincinnati Children's

Nuwellis Announces Pricing of $2.0 Million Offering Priced At-The-Market Under Nasdaq Rules

Jul 24, 2024, 8:02 AM EDT - 1 year ago

Nuwellis Announces Pricing of $2.0 Million Offering Priced At-The-Market Under Nasdaq Rules

Nuwellis, Inc. To Report Second Quarter 2024 Financial Results on August 13, 2024

Jul 23, 2024, 4:10 PM EDT - 1 year ago

Nuwellis, Inc. To Report Second Quarter 2024 Financial Results on August 13, 2024

Nuwellis Marks First Commercial Sale of QUELIMMUNE™ Therapy to Cincinnati Children's

Jul 17, 2024, 9:00 AM EDT - 1 year ago

Nuwellis Marks First Commercial Sale of QUELIMMUNE™ Therapy to Cincinnati Children's

Nuwellis Announces Reverse Stock Split

Jun 26, 2024, 8:45 AM EDT - 1 year ago

Nuwellis Announces Reverse Stock Split

Nuwellis Secures New Patent for Innovative Pediatric Continuous Renal Replacement Therapy, Vivian™

Jun 25, 2024, 9:00 AM EDT - 1 year ago

Nuwellis Secures New Patent for Innovative Pediatric Continuous Renal Replacement Therapy, Vivian™

DaVita, Nuwellis Extend Pilot Collaboration for Aquadex

Jun 11, 2024, 12:46 PM EDT - 1 year ago

DaVita, Nuwellis Extend Pilot Collaboration for Aquadex

DVA

Nuwellis and DaVita Extend Supply and Collaboration Agreement Pilot Phase

Jun 6, 2024, 9:00 AM EDT - 1 year ago

Nuwellis and DaVita Extend Supply and Collaboration Agreement Pilot Phase

Nuwellis Announces Expansion of Ultrafiltration Program to Pediatric Patients at One of the Largest Hospital Networks in Florida

May 14, 2024, 9:00 AM EDT - 1 year ago

Nuwellis Announces Expansion of Ultrafiltration Program to Pediatric Patients at One of the Largest Hospital Networks in Florida

Nuwellis Announces Purchase Agreement with a 50 Hospital Network for Aquadex Ultrafiltration Therapy

May 9, 2024, 9:00 AM EDT - 1 year ago

Nuwellis Announces Purchase Agreement with a 50 Hospital Network for Aquadex Ultrafiltration Therapy

Nuwellis, Inc. (NUWE) Q1 2024 Earnings Call Transcript

May 7, 2024, 10:29 AM EDT - 1 year ago

Nuwellis, Inc. (NUWE) Q1 2024 Earnings Call Transcript

Nuwellis, Inc. Announces First Quarter 2024 Financial Results

May 7, 2024, 8:00 AM EDT - 1 year ago

Nuwellis, Inc. Announces First Quarter 2024 Financial Results

Nuwellis Announces Closing of $2.7 Million Public Offering

Apr 30, 2024, 6:09 PM EDT - 1 year ago

Nuwellis Announces Closing of $2.7 Million Public Offering

IAMEXITLIQUIDITY
IAMEXITLIQUIDITY Aug. 18 at 1:44 PM
$NUWE she will go shortly... need to recoup some $CRE losses... she's a beauty when she runs and has no reason not to today
0 · Reply
bghom
bghom Aug. 18 at 1:19 PM
Sometimes it feels like $BGM is the sleeper in this group. While $WULF has Google, $BTAI has FDA, and $NUWE has low float hype—$BGM is still sitting low waiting for a spark.
0 · Reply
ogagbolo
ogagbolo Aug. 18 at 1:04 PM
$NUWE has all the ingredients for a squeeze. Low float, new patent, and traders piling in. Will it hold up longer than the last time, or fade fast? Watching with $BGM and $WULF on the side.
0 · Reply
hajjah
hajjah Aug. 18 at 12:55 PM
$NUWE traders are hyped but cautious—reverse splits in the past still haunt some. Still, low float can mean fireworks. Compared to $BGM and $BTAI, this one’s pure volatility play.
0 · Reply
roy30
roy30 Aug. 18 at 12:46 PM
$NUWE might only need volume to go crazy. That patent news and low float setup is hard to ignore. Watching this alongside $WULF and $BGM could create some wild sympathy plays.
0 · Reply
ola31
ola31 Aug. 18 at 12:28 PM
Noticing a rotation: $BTAI for biotech bulls, $NUWE for low float momentum, $WULF for AI/HPC, $BGM for robotics. Different themes, same energy—speculation is everywhere.
0 · Reply
BB_88_
BB_88_ Aug. 18 at 12:23 PM
$NUWE this hasn’t made a rocket run in a long long time
0 · Reply
anthony78w
anthony78w Aug. 18 at 12:23 PM
$BTAI bulls calling this “the beginning of the squeeze.” FDA optimism + Phase 3 talk + possible buyout chatter = fuel. Combine that biotech momentum with $NUWE’s volatility and $BGM’s robotics angle, and small caps are buzzing today.
0 · Reply
ophinh
ophinh Aug. 18 at 12:19 PM
$NUWE low float madness is here again. Patent win + volatility = recipe for fireworks. Watching how this trades compared to $BGM and $WULF, both popularity for totally different reasons.
0 · Reply
topstockalerts
topstockalerts Aug. 18 at 12:02 PM
$NUWE waking up..
0 · Reply
asdghsadf
asdghsadf Aug. 18 at 11:57 AM
$NUWE 👇
0 · Reply
mikesterz7
mikesterz7 Aug. 18 at 11:52 AM
$NUWE The virtual presentation will be delivered by John Erb, President and Chief Executive Officer, on Thursday, August 21, 2025 at 2:40 PM ET. The event is part of a broader virtual conference taking place from August 19-21, 2025.
0 · Reply
tdfeq131995
tdfeq131995 Aug. 18 at 11:30 AM
$NUWE ↓
0 · Reply
frankyboyz
frankyboyz Aug. 18 at 11:27 AM
Lottos down here 5.60’s $NUWE 5.4 must hold lets see if gets again love or i go back to pool 😁
0 · Reply
bbghft
bbghft Aug. 18 at 11:21 AM
$NUWE ⬇️⬇️⬇️⬇️
0 · Reply
Russell007xx
Russell007xx Aug. 18 at 11:10 AM
$NUWE like i said, you will see a fake up and quickly fade away, so be careful of investhis this 💩
0 · Reply
GlobalMarketBulletin
GlobalMarketBulletin Aug. 18 at 11:06 AM
$NUWE With growing pediatric adoption, & a focus on outpatient heart failure, Nuwellis is preparing itself as a leader in medical technology. https://globalmarketbulletin.com/investors-are-eyeing-nuwellis-nuwe-as-the-next-big-medical-innovation-stock/
0 · Reply
Profitrip
Profitrip Aug. 18 at 10:46 AM
$NUWE low float / on watch
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 18 at 10:45 AM
$NUWE gappers
0 · Reply
Russell007xx
Russell007xx Aug. 18 at 9:42 AM
$NUWE just be aware before buying this stock, management is trying to do a fake early pump before dilution
1 · Reply
BootsyBee
BootsyBee Aug. 18 at 8:37 AM
$NUWE Per 10Q filed 8/14 - The number of outstanding shares of the registrant’s common stock, $0.0001 par value, as of August 8, 2025 was 902,665.
0 · Reply
bazooka007
bazooka007 Aug. 18 at 8:35 AM
$NUWE 65k pre market volume so far. Interesting start into the new week.
0 · Reply